SPOTLIGHT -
Ms Duerr is the editorial director of Psychiatric Times.
Looking Ahead to the ASCP Annual Meeting With Joseph F. Goldberg, MD, and Anita H. Clayton, MD
Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.
Nassir Ghaemi, MD, MPH, Shares What’s Not Exciting in Psychiatry—and What Would Be Exciting
Although there are topics in psychiatry that not exciting, Dr Ghaemi sees plenty of opportunities.
Study Finds Zuranolone Effective for Anhedonia in Patients With PPD
Poster presented at the APA Annual Meeting finds zuranolone effective for anhedonia associated with PPD.
Nassir Ghaemi, MD, MPH, Explores SRIs at APA Annual Meeting
Dr Nassir Ghaemi explores the long-term effects and safety of serotonin reuptake inhibitors, revealing benefits and potential risks.
Helping Clinicians and Patients Overcome Insurance Barriers to Mental Health Care
A nonprofit aims to support clinicians and patients with insurance coverage for evidence-based medicine.
Novel PDE10A Inhibitor for Acute Schizophrenia Exacerbation Presented at APA Annual Meeting
Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.
Poster at APA Annual Meeting Explores the Use of GLP-1 Agonists for Antipsychotic-Associated Metabolic Issues
Can GLP-1 agonists support patients on antipsychotics? Amir Meftah, MD, and colleagues explore its use.
Exploring New Frontiers in Depression Treatment at the APA Annual Meeting: A Call for Precision Psychiatry
At the APA Annual Meeting, Dana Hilt, MD, PhD, explores the notion of precision psychiatry in depression treatment.
New Research on Addressing Metabolic Issues Associated With Antipsychotics at APA Annual Meeting
Amir Meftah, MD, discusses the possibility of GLP-1s for addressing metabolic issues associated with antipsychotics.
Targeting Brain Cortisol: Xanamem Shows Promise in Depression and Alzheimer Disease
Dana Hilt, MD, PhD, discusses data on Xanamem’s impact on cortisol and its potential use in MDD at the APA Annual Meeting.
Beyond the Usual Psychedelic Suspects: What Psychiatrists Need to Know
What should you know about the lesser known psychedelics? Clinical insights from Jacob Perlson, MD, MPH, at the APA Annual Meeting.
Alto Neuroscience Advances Four Phase 2 Trials With Precision Psychiatry Focus
Biomarker Mechanism for ALTO-300 in Precision Psychiatry Study Proves Promising in MDD Treatment, According to Amit Etkin, MD, PhD
Etkin describes precision psychiatry data for MDD presented at the Society for Biological Psychiatry Annual Meeting.
Amit Etkin, MD, PhD, Shares Insights Into EEG-Based Biomarkers to Tackle Placebo Effects in Psychiatry
Cobenfy as an Adjunctive Agent in Schizophrenia: Peter J. Weiden, MD, Shares Insights on the Latest Findings
Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.
Re-Affirming Evidence-Based Psychiatric Care: A Joint Statement on Psychotropic Medication Safety
Joseph Goldberg, MD, discusses the recent joint statement on evidence-based medicine and psychotropic safety.
The FDA Removal of the Clozapine REMS Requirement: An Expert Perspective
The FDA decision to remove the clozapine REMs requirement has left many questions. Chelsie Monroe, MSN, APN, PMHNP-BC, sheds some light on it.
John J. Miller, MD, Responds to Statement on Psychotropic Medication Concerns
Psychiatric Times Editor in Chief John J. Miller, MD, shares thoughts on psychiatry's response to the recent executive order.
Psychiatric Organizations Respond to Federal Concerns Over Psychotropic Medications, SAMHSA Budget Cuts
Joint statements from leading psychiatric organizations voice concern about impact on patient care from executive orders and budget cuts.
A Renaissance for Schizophrenia Treatment
Chelsea Monroe, MSN, APN, PMHNP-BC, discusses the current renaissance in treating schizophrenia.
FDA Officially Removes REMS Requirement for Clozapine
Determining risks outweigh the benefits, the FDA is removing the clozapine REMS requirement.
Panel Shares Top 7 Insights Into Addressing PTSD
Check out these 7 insights and perspectives on recognizing and treating PTSD.
Psychiatric Times Welcomes New Section Editor
Stephen Mateka, DO, Psychiatric Times' new Child & Adolescent Psychiatry Section Editor, shares thoughts and insights.
Positive Results in Phase 2b Trial of Psychedelic Agent GH001 for Treatment-Resistant Depression
A recent phase 2b trial of GH001 showed promising results for treatment-resistant depression, demonstrating rapid and sustained effects with a favorable safety profile.
Disappointing Data From Phase III CONNEX for Iclepertin in Addressing Cognition Impairment in Schizophrenia
Although iclepertin was found to be well tolerated, the agent did not meet endpoints.
Celebrating 40 Years: Looking Forward
Psychiatric Times: Supporting clinicians, promoting conversations, and improving patient care over the past 40 years.
Study Finds ERPOs Can Prevent Suicide by Firearms
Extreme risk protection orders may be an effective suicide prevention tool.
Ibogaine Found to Reduce Mood Disorder and PTSD Symptoms, Consumption of Alcohol in Patients With Alcohol Use Disorder
How can Ibogaine help patients with Alcohol Use Disorder, specifically in veterans?
Physical Activity, Lifestyle Factors, and the Aging Brain
What effects do lifestyle factors have on brain aging and neuropsychiatic symptoms?
SPN-820: Rapid-Acting Antidepressant Shows Promising Phase 2 Results
Data presented at ACNP meeting demonstrated safety, tolerability, and efficacy for SPN-820 for MDD.